Target intelligence / Profile preview

Hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6)

Target: HSD17B6
Molecular classification: Enzyme, Short-chain dehydrogenase/reductase (SDR) family, Oxidoreductase, Retinol dehydrogenase

Overview

Hydroxysteroid 17-beta dehydrogenase 6 is an NAD+-dependent oxidoreductase and epimerase involved in androgen catabolism, notably catalyzing the conversion of 3 alpha-adiol to dihydrotestosterone (DHT) and androsterone to epi-androsterone. It is a member of the short-chain dehydrogenase/reductase family and also displays retinol dehydrogenase activity[4][5]. HSD17B6 regulates steroid hormone levels and has increasingly recognized roles in cancer biology, particularly as a tumor suppressor in lung adenocarcinoma, inhibiting cell proliferation, migration, invasion, and epithelial-mesenchymal transition. Suppression of HSD17B6 in tumors correlates with poor prognosis and aggressive disease. Its function suggests potential as a prognostic biomarker and future therapeutic target[2][4][5].

Other names: 17-beta-hydroxysteroid dehydrogenase type 6HSD17B6RODHSDR9C6Hydroxysteroid (17-beta) dehydrogenase 63-alpha->beta-hydroxysteroid epimeraseOxidative 3-alpha-hydroxysteroid dehydrogenaseShort-chain dehydrogenase/reductase family 9C member 6Retinol dehydrogenaseNAD+-dependent 3 alpha-hydroxysteroid dehydrogenase

Mechanism of action

Enzyme modulation to alter androgen biosynthesis (potential future mechanism for drugs); Suppression of cell proliferation/metastasis via upregulation in cancer models.

Biological functions

Androgen catabolism (conversion of 3 alpha-adiol to dihydrotestosterone)Epimerization of androsterone to epi-androsteroneRetinol dehydrogenase activityModulation of steroid hormone levelsSuppression of cell proliferation and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma (tumor suppressor function)

Disease associations

Cancer (notably lung adenocarcinoma, hepatocellular carcinoma, ovary sarcoma, ovarian endometrioid stromal sarcoma)Polycystic ovary syndrome (suggested)

Safety considerations

No specific safety concerns identified for therapeutic targeting in the retrieved sources. Enzyme modulation may alter systemic steroid levels, posing theoretical risks (based on related enzyme research).

Biomarkers

HSD17B6 expression levels as a prognostic marker for lung adenocarcinoma (and potentially other tumors)

Beyond the preview

Go deeper on Hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6).

Explore the full profile